Leaderboards/Chronic Myeloid Leukemia Treatments

Chronic Myeloid Leukemia Treatments

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Yi‐Fen Chiang
Taipei Medical University
2
Bashir A. Bashir
Omdurman Ahlia University
3
Hyun-Jin Kwon
Korea Pharma (South Korea)
4
Alicia Annamalay
Seattle Center Foundation
5
Saubia Fathima
Mayo Clinic in Arizona
6
Edoardo Pennesi
Princess Máxima Center
7
Ruiqi Zhu
Soochow University
8
Aleksandra E Kamizela
Wellcome Sanger Institute
9
Anastasia Geladaris
Fraunhofer Institute for Translational Medicine and Pharmacology
10
Stephanie Sembill
Universitätsklinikum Erlangen

Papers

1
Hinokitiol Inhibits Breast Cancer Cells In Vitro Stemness-Progression and Self-Renewal with Apoptosis and Autophagy Modulation via the CD44/Nanog/SOX2/Oct4 Pathway
International Journal of Molecular Sciences|2024
80 cit.
2
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
Haematologica|2024
18 cit.
3
Hinokitiol modulates Nrf2/HO-1 signaling, autophagy, and URAT1 in hyperuricemia and oxidative stress models of renal injury
Free Radical Biology and Medicine|2025
8 cit.
4
Protective Effects of an Oligo-Fucoidan-Based Formula against Osteoarthritis Development via iNOS and COX-2 Suppression following Monosodium Iodoacetate Injection
Marine Drugs|2024
7 cit.
5
Impact of Adlay-Based Formula on Pain and Discomfort in Women with Dysmenorrhea: A Randomized Controlled Trial
Nutrients|2024
4 cit.
6
Protective Effects of L-Cysteine Against Cisplatin-Induced Oxidative Stress-Mediated Reproductive Damage
Antioxidants|2024
4 cit.
7
Publication in New England Journal of Medicine (2026) [3 citations, W7140322130]
New England Journal of Medicine|2026
3 cit.
8
Publication in Leukemia (2024) [1 citation, W4399134410]
Leukemia|2024
1 cit.
9
Publication in Annals of Oncology (2024) [W4402561335]
Annals of Oncology|2024
0 cit.
10
Publication in Annals of Oncology (2025) [W4415940008]
Annals of Oncology|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Kathryn G. Roberts
St. Jude Children's Research Hospital
2
marie Magdelaine Coude
Délégation Paris 7
3
Yan‐Zeng Jia
Eisai (United States)
4
Mallory Campbell
Pancreatic Cancer Action Network
5
Alica Joana Emhardt
LMU Klinikum
6
Isidro Cortés‐Ciriano
European Bioinformatics Institute
7
Nicholas J. Short
The University of Texas MD Anderson Cancer Center
8
Linda Geironson
Lund University
9
Mikael N.E. Sommarin
Lund University
10
Claudia A. Staab-Weijnitz
German Center for Lung Research

Papers

1
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML
Journal of Clinical Oncology|2024
146 cit.
2
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
Blood Advances|2022
112 cit.
3
De novo detection of somatic mutations in high-throughput single-cell profiling data sets
Nature Biotechnology|2023
101 cit.
4
Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA
Cancer Discovery|2023
90 cit.
5
Ultrasensitive <scp>NGS MRD</scp> assessment in Ph+  <scp>ALL</scp> : Prognostic impact and correlation with <scp>RT‐PCR</scp> for <i>BCR::ABL1</i>
American Journal of Hematology|2023
73 cit.
6
Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution
Cell|2025
69 cit.
7
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Journal of Hematology & Oncology|2023
50 cit.
8
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations
Acta Haematologica|2022
38 cit.
9
Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with <i>FLT3</i>-Mutated Acute Myeloid Leukemia
Blood|2022
38 cit.
10
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
Blood Advances|2024
33 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center
2
Brian Druker
Oregon Health & Science University
3
Jörge E. Cortes
Augusta University Health
4
Charles L. Sawyers
Memorial Sloan Kettering Cancer Center
5
Moshe Talpaz
University of Michigan
6
David Baltimore
California Institute of Technology
7
Andreas Hochhaus
Jena University Hospital
8
Timothy P. Hughes
Royal Adelaide Hospital
9
Owen N. Witte
Howard Hughes Medical Institute
10
James D. Griffin
Harvard University

Papers

1
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
New England Journal of Medicine|2001
5.2k cit.
2
NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses
Proceedings of the National Academy of Sciences|2006
4.3k cit.
3
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Nature Medicine|1996
3.7k cit.
4
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
New England Journal of Medicine|2003
3.6k cit.
5
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
New England Journal of Medicine|2006
3.5k cit.
6
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Science|1996
3.1k cit.
7
NF-κB: Ten Years After
Cell|1996
3k cit.
8
Multiple nuclear factors interact with the immunoglobulin enhancer sequences
Cell|1986
2.8k cit.
9
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins
Cell|1989
2.7k cit.
10
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
New England Journal of Medicine|2001
2.7k cit.

Reagents for Chronic Myeloid Leukemia Treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Phospho-ALK (Tyr1586) Antibody

Cited in 10 papers
#3343$362
View Evidence →
Cell Signaling TechnologyEvidence 64

Phospho-Stat5 (Tyr694) (C11C5) Rabbit Monoclonal Antibody

Cited in 10 papers
#9359$168,971
View Evidence →
Cell Signaling TechnologyEvidence 67

Stat5 (D2O6Y) Rabbit Monoclonal Antibody

Cited in 10 papers
#94205$152,844
View Evidence →

🌟 All-Time

Most validated

Santa Cruz Biotechnology

c-Abl (24-11)

Cited in 20 papers
#sc-23
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-Tyrosine Mouse Monoclonal Antibody (P-Tyr-100) (Alexa Fluor® 488 Conjugate)

Cited in 11 papers
#9414$493
View Evidence →
Cell Signaling TechnologyEvidence 61

p56Dok-2 Antibody

Cited in 10 papers
#3914$317
View Evidence →